165 related articles for article (PubMed ID: 24926795)
1. Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug.
Amable L; Fain J; Gavin E; Reed E
Oncol Rep; 2014 Aug; 32(2):469-74. PubMed ID: 24926795
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
3. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
4. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
5. Interference with SMO increases chemotherapy drug sensitivity of A2780/DDP cells by inhibiting the Hh/Gli signaling pathway.
Ma S; Liu D; Tan W; Du B; Liu W; Li W; Jiao Y
J Cell Biochem; 2020 Jun; 121(5-6):3256-3265. PubMed ID: 31904145
[TBL] [Abstract][Full Text] [Related]
6. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB
Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296
[TBL] [Abstract][Full Text] [Related]
7. GLI1 upregulates C-JUN through a specific 130-kDa isoform.
Amable L; Gavin E; Kudo K; Meng E; Rocconi RP; Shevde LA; Reed E
Int J Oncol; 2014 Mar; 44(3):655-61. PubMed ID: 24366538
[TBL] [Abstract][Full Text] [Related]
8. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
Parker RJ; Eastman A; Bostick-Bruton F; Reed E
J Clin Invest; 1991 Mar; 87(3):772-7. PubMed ID: 1999494
[TBL] [Abstract][Full Text] [Related]
9. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
10. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
[TBL] [Abstract][Full Text] [Related]
12. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
[TBL] [Abstract][Full Text] [Related]
13. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
Stordal B; Hamon M; McEneaney V; Roche S; Gillet JP; O'Leary JJ; Gottesman M; Clynes M
PLoS One; 2012; 7(7):e40717. PubMed ID: 22792399
[TBL] [Abstract][Full Text] [Related]
14. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
16. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Jaehde U
J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
[TBL] [Abstract][Full Text] [Related]
17. Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells.
Gong TT; Liu XD; Zhan ZP; Wu QJ
Exp Cell Res; 2020 Aug; 393(2):112061. PubMed ID: 32437713
[TBL] [Abstract][Full Text] [Related]
18. Gli affects the stemness and prognosis of epithelial ovarian cancer via homeobox protein NANOG.
Zhao H; Li N; Pang Y; Zhao J; Wu X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313950
[TBL] [Abstract][Full Text] [Related]
19. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
20. Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells.
Pan H; Kim E; Rankin GO; Rojanasakul Y; Tu Y; Chen YC
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
